Explain this page
Arphra AIPlain-English read on Zimmer Biomet Holdings, Inc.’s valuation06-16today
- Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term5d
- Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock7d
- Zimmer Biomet: Does Slow And Steady Still Win The Race?8d
- Zimmer Biomet Holdings, Inc. (ZBH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript15d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$253.56
+189.55% vs spot
Recommendation
Strong Buy
18 of 19 methods
Method spread
8bull8bear
±5% threshold
Analyst PT consensus: $97.90 (+11.80%)
Candlestick · 1Y
Open in chart workstation →ZBH
87.97-4.73%H 108.29L 79.12MA50 87.05MA200 92.51Avg vol 2.0M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.55% | -0.32% | +2.42% | -0.26% | -2.08% | -2.61% | -4.30% | -39.18% | -45.12% | -25.35% | +203.33% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$1.1M
8 txns
Net flow
−$1.1M
Aftermarket
LiveLast trade
$88.28
1 sh
Bid
$85.51
1 sh
Ask
$90.01
50 sh
Spread
$4.500
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $2.09B | $238.1M | $1.22 |
| Q4 Dec 2025 | $2.24B | $139.5M | $0.70 |
| Q3 Sep 2025 | $2B | $230.9M | $1.16 |
| Q2 Jun 2025 | $2.08B | $152.8M | $0.77 |
| Q1 Mar 2025 | $1.91B | $182M | $0.91 |
| Q4 Dec 2024 | $2.02B | $239.5M | $1.20 |
Analyst view
DB · price_targets + analyst_gradesConsensus target
$97.90
+11.80% upside
Low
$83.00
Median
$93.50
High
$120.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Termzacks.com·Jun 18, 2026
- Here's Why Zimmer Biomet (ZBH) is a Strong Value Stockzacks.com·Jun 16, 2026
- Zimmer Biomet: Does Slow And Steady Still Win The Race?seekingalpha.com·Jun 16, 2026
- Zimmer Biomet Holdings, Inc. (ZBH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 08, 2026
- Zimmer Biomet Holdings, Inc. (ZBH) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 13, 2026
- Zimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year Endprnewswire.com·May 12, 2026
- Zimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year Endprnewswire.com·May 12, 2026
- Why Zimmer Biomet (ZBH) is a Top Growth Stock for the Long-Termzacks.com·May 04, 2026
Financial scores
DBJun 24, 2026Altman Z
2.40
Grey
≥ 3.0 safe · 1.81–3.0 grey · < 1.81 distress
Piotroski F
8/9
Strong
≥ 7 strong · 4–6 average · < 4 weak
Peers
- UTHRUnited Therapeutics Corporation$570.40$25B
- DXCMDexCom, Inc.$61.35$23.67B
- DGXQuest Diagnostics Incorporated$192.67$21.33B
- WSTWest Pharmaceutical Services, Inc.$300.68$21.24B
- LHLabcorp Holdings Inc.$255.84$21.06B
- STESTERIS plc$214.40$21.04B
- ILMNIllumina, Inc.$135.78$20.63B
- INCYIncyte Corporation$96.91$19.36B
Total assets
$23.09B
Total debt
$7.52B
Cash & equiv
$591.9M
Operating CF
$1.7B
Free cash flow
$1.47B
Buybacks
-$487M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Winkler Lori officer: SVP and CHRO | Sell | 2,650 | $250.85K | Mar 12, 2026 |
Yi Sang officer: Group President, Asia Pacific | Sell | 1,000 | $96.49K | Feb 12, 2026 |
Yi Sang officer: Group President, Asia Pacific | Sell | 1,200 | $124.3K | Sep 11, 2025 |
Winkler Lori officer: SVP and CHRO | Sell | 1,500 | $156.23K | Sep 08, 2025 |
Winkler Lori officer: SVP and CHRO | Sell | 1,500 | $153.74K | Aug 18, 2025 |
Yi Sang officer: Group President, Asia Pacific | Sell | 800 | $74.01K | Jun 13, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $8.23B | $1.36B | $705.2M | $3.55 | +8.57% |
| FY 2024 | $7.68B | $1.29B | $903.8M | $4.43 | +11.77% |
| FY 2023 | $7.39B | $1.28B | $1.02B | $4.88 | +13.85% |
| FY 2022 | $6.94B | $696.3M | $231.4M | $1.10 | +3.33% |
| FY 2021 | $6.83B | $860.3M | $401.6M | $1.91 | +5.88% |